Compare FSBC & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSBC | OMER |
|---|---|---|
| Founded | 2002 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 741.2M | 628.9M |
| IPO Year | 2021 | 2009 |
| Metric | FSBC | OMER |
|---|---|---|
| Price | $37.78 | $9.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $37.83 | $27.50 |
| AVG Volume (30 Days) | 58.0K | ★ 1.7M |
| Earning Date | 01-26-2026 | 11-13-2025 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | ★ 19.76 | N/A |
| EPS | ★ 2.70 | N/A |
| Revenue | ★ $141,930,000.00 | N/A |
| Revenue This Year | $34.35 | N/A |
| Revenue Next Year | $17.79 | N/A |
| P/E Ratio | $13.82 | ★ N/A |
| Revenue Growth | ★ 25.41 | N/A |
| 52 Week Low | $22.22 | $2.95 |
| 52 Week High | $37.74 | $13.60 |
| Indicator | FSBC | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 68.34 | 52.71 |
| Support Level | $34.49 | $9.31 |
| Resistance Level | $35.48 | $11.71 |
| Average True Range (ATR) | 1.04 | 0.64 |
| MACD | 0.32 | -0.11 |
| Stochastic Oscillator | 94.21 | 15.45 |
Five Star Bancorp is a bank holding company through its subsidiary it operates in California state-chartered non-member bank. The Company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts. The group has one reportable operating segment; Banking.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.